What we do Anuh Pharma Ltd manufactures and sells Active Pharmaceutical Ingredients (APIs) including antibiotics, anti-tuberculosis, anti-malarial, and corticosteroids, serving global pharmaceutical markets. |
Founded in 1,960 |
Market share Leading API manufacturer in India with significant presence in global regulated and semi-regulated markets including Europe and Latin America. |
Problem solved Provides high-quality pharmaceutical raw materials to facilitate affordable and effective medicines globally, addressing antimicrobial and chronic disease treatment needs. |
Top clients or who we serve Serves pharmaceutical companies worldwide, including regulated markets like Europe and the US; business-to-business (B2B) model. |
Key management Mr. Ritesh Shah (Joint MD, MBA Chemistry), Mr. Vivek Shah (Joint MD, MSc Biotechnology), Mr. Darshan Rampariya (CFO, CA), Dr. Sanjay Vaidya (GM R&D). |
Our journey and innovations Since 1960, expanded capacities, achieved multiple WHO and EDQM certifications, commissioned modern facilities, and introduced 40 new products by FY25. |
Where we operate Exports to 59+ countries including Mexico, Brazil, Europe, Africa, Asia, and North and Latin America. |
Top products or what we offer Macrolides like Erythromycin salts, Anti-TB drugs (Pyrazinamide, Isoniazid), Anti-malarials, Corticosteroids, Ambroxol HCL, and Anti-diabetics like Gliclazide. |
Top brands Erythromycin salts (market leader), Pyrazinamide (WHO prequalified), Sulfadoxine, Ambroxol HCL, Allopurinol, with multiple EDQM and WHO approvals. |
Raw materials needed Chemical precursors for APIs including antibiotics and steroid intermediates. |
Raw materials supplier Multiple suppliers with backward integration in key product lines. |
Recurring vs cyclical contribution Revenue largely from recurring long-term contracts with pharmaceutical firms and continuous batch manufacturing cycles. |
Our industry position Among top Indian API manufacturers with expanding global regulatory approvals and certifications, strong export growth. |
Financial highlights FY25 revenue Rs. 661.51 Cr, profit after tax Rs. 47.35 Cr, modest margin pressure but stable EBITDA near Rs. 70 Cr. |
Geographical revenue split Around 55% revenue from exports; key regions include Europe (24%), Africa (28%), Asia (30%), and Latin America (10%). |
Order book - |
Whats driving growth Capacity expansions, regulatory approvals, new product launches, enhanced global demand, and operational efficiencies. |
Our future plans Focus on innovation, product pipeline expansion with lifestyle and complex APIs, inorganic growth, and market penetration growth. |
Our green promise Investments in solar power, Zero Liquid Discharge systems, water and energy conservation, and environment-focused certifications. |
Our people and values ~250 employees fostering safety, training, diversity with zero major safety incidents and robust governance. |
Key challenges ahead Managing margin pressures, regulatory compliance, raw material cost volatility, and global market competition. |
Interesting facts Successfully passed USFDA inspection with zero observations in 2026; operates nine API blocks and two intermediate blocks. |
Risks and strategy Mitigates regulatory risk via compliance, invests in R&D to diversify portfolio; focuses on sustainable operations and strong customer relationships. |
